Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0AK4K
|
|||
| Former ID |
DIB020615
|
|||
| Drug Name |
ONO-AE3-208
|
|||
| Synonyms |
402473-54-5; 4-Cyano-2-[[2-(4-fluoro-1-naphthalenyl)-1-oxopropyl]amino]benzenebutanoic acid; ONO AE3 208; SCHEMBL679969; GTPL1942; CTK1D4873; KS-00001DVO; DTXSID20435810; MolPort-035-765-695; 3952AH; AKOS024457689; 4-[4-cyano-2-[2-(4-fluoronaphthalen-1-yl)propanoylamino]phenyl]butanoic Acid; CS-0315; NCGC00378671-02; HY-50901; AK547789; DB-030557; FT-0715398; ONO-AE3-208, > W-5560; 473O545; 4-(4-Cyano-2-(2-(4-fluoronaphthalen-1-yl)propanamido)phenyl)butanoic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL
|
||
| Formula |
C24H21FN2O3
|
|||
| Canonical SMILES |
CC(C1=CC=C(C2=CC=CC=C21)F)C(=O)NC3=C(C=CC(=C3)C#N)CCCC(=O)O
|
|||
| InChI |
1S/C24H21FN2O3/c1-15(18-11-12-21(25)20-7-3-2-6-19(18)20)24(30)27-22-13-16(14-26)9-10-17(22)5-4-8-23(28)29/h2-3,6-7,9-13,15H,4-5,8H2,1H3,(H,27,30)(H,28,29)
|
|||
| InChIKey |
MTDIMKNAJUQTIO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 402473-54-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin E2 receptor EP3 (PTGER3) | Target Info | Antagonist | [2] |
| Prostaglandin E2 receptor EP4 (PTGER4) | Target Info | Antagonist | [2] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Inflammatory mediator regulation of TRP channels | ||||
| Renin secretion | ||||
| Pathways in cancer | ||||
| Calcium signaling pathway | ||||
| cAMP signaling pathway | ||||
| Regulation of lipolysis in adipocytes | ||||
| NetPath Pathway | FSH Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| IL4 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (s) signalling events | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| GPCRs, Class A Rhodopsin-like | ||||
| Vitamin D Receptor Pathway | ||||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1942). | |||
| REF 2 | The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut. J Clin Invest. 2002 Apr;109(7):883-93. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.